top of page


Genentech licenses Alector brain-penetrant Parkinson's programme in deal worth up to $1.27bn
Genentech has licensed Alector's brain-penetrant AL050 programme in a neurodegeneration deal worth up to $1.27 billion.

nuaxia
Oct 62 min read


FDA approves Juvmo for adults with Parkinson's disease
The approval introduces a selective dopamine D1/D5 receptor partial agonist as a new oral treatment option for adults with Parkinson's disease.

nuaxia
Sep 281 min read


SK Biopharmaceuticals licenses Parkinson's candidate 1ST-104 in deal worth up to $314.8m
SK Biopharmaceuticals has secured exclusive global rights to 1ST Biotherapeutics' preclinical Parkinson's disease candidate 1ST-104 in a deal worth up to $314.8 million.

nuaxia
Sep 242 min read
bottom of page